Endorphin System

Overview

The endorphin system is the body's native opioid machinery. It comprises three families of peptide ligands — beta-endorphin, enkephalins, and dynorphins — and three classical receptor subtypes — mu (μ), delta (δ), and kappa (κ) — all of them Gi/Go-coupled G-protein coupled receptors. Together these molecules set resting nociceptive thresholds, scale the euphoric response to reward, organize social attachment, and brake excessive hypothalamic-pituitary-adrenal axis activation during stress.

The word "endorphin" is a contraction of "endogenous morphine," and the historical discovery arc reflects that lineage. The isolation of enkephalin by Hughes and Kosterlitz in 1975 and the subsequent identification of beta-endorphin confirmed that the brain manufactured its own opiate ligands long before anyone harvested poppies. Peptides such as Selank, Melanotan II, DSIP, and BPC-157 are investigated for indirect effects on opioid tone, analgesia, and reward-circuit function.

Three Ligand Families, Three Precursors

Proopiomelanocortin (POMC). This precursor is cleaved in the pituitary and arcuate nucleus to yield beta-endorphin, ACTH, and alpha-MSH. Beta-endorphin is the longest and most potent of the endogenous opioids, binding preferentially to mu receptors. POMC cleavage also generates the melanocortins that peptides like Melanotan II mimic.

Proenkephalin. Processed to yield met-enkephalin and leu-enkephalin, short pentapeptides that bind preferentially to delta receptors and are widely distributed in the CNS, adrenal medulla, and gut.

Prodynorphin. Processed to yield dynorphin A, dynorphin B, and neoendorphins. Dynorphins bind preferentially to kappa receptors, and their signaling drives the dysphoric, stress-reactive arm of the opioid system — a pharmacology quite distinct from the euphoria associated with mu activation.

How It Works

Biosynthesis. Precursor proteins are synthesized in the rough ER, packaged into secretory vesicles, and processed by prohormone convertases PC1 and PC2 into the mature peptides en route to release sites. Neurons can regulate which mature products they produce by differential convertase expression.

Release. Opioid peptides are stored in large dense-core vesicles, not the small synaptic vesicles that carry classical transmitters. Their release typically requires higher-frequency firing and sustained calcium entry, consistent with their role as peptidergic volume-transmission signals that diffuse beyond the immediate synapse — the mechanism covered under neurotransmission.

Receptor action. All three opioid receptors couple to Gi/Go. Downstream effects include adenylate cyclase inhibition (lowering cAMP), GIRK potassium channel opening (hyperpolarizing the neuron), and voltage-gated calcium channel closure (reducing neurotransmitter release). The net effect is presynaptic and postsynaptic inhibition of neurons that normally transmit pain, stress, or — paradoxically — inhibition onto inhibitory neurons, disinhibiting dopamine release in the ventral tegmental area.

Termination. Endogenous opioid peptides are degraded by cell-surface peptidases including neutral endopeptidase (neprilysin) and aminopeptidase N. Peptidase inhibitors can prolong endogenous opioid signaling without directly activating receptors, a mechanism some investigators attribute to Selank.

The Three Receptors

Mu (μ). The classical analgesic receptor. Dense in the periaqueductal gray, rostral ventromedial medulla, and dorsal horn of the spinal cord — the descending pain-modulatory axis covered under pain signaling. Mu activation also disinhibits VTA dopamine neurons, producing the euphoria that drives opioid reinforcement.

Delta (δ). Broadly distributed across the cortex, amygdala, and striatum. Delta agonism produces mild analgesia, anxiolysis, and antidepressant-like effects without the full respiratory depression liability of mu activation.

Kappa (κ). Enriched in the striatum, hypothalamus, and claustrum. Kappa activation produces analgesia but also dysphoria, diuresis, and sedation. Chronic stress upregulates dynorphin and kappa signaling, contributing to anhedonia.

Exercise, Stress, and Social Bonding

The "runner's high" is plausibly mediated in part by beta-endorphin release, though more recent evidence emphasizes the endocannabinoid system as well. Acute stress triggers rapid POMC cleavage in the pituitary, releasing beta-endorphin alongside ACTH — the same precursor produces both the stress hormone axis driver and its endogenous analgesic brake. Social bonding in parent-infant and pair-bonded contexts engages mu receptor signaling in the striatum, which is why low-dose naltrexone can alter social reward processing.

Tolerance and Dependence

Sustained opioid receptor activation triggers receptor desensitization through β-arrestin recruitment, receptor internalization, and adenylate cyclase superactivation. These molecular adaptations underlie tolerance (needing more drug for the same effect), dependence (withdrawal symptoms on cessation), and the rebound hyperactivation of cAMP that drives much of the acute withdrawal syndrome. Biased agonists that engage G-protein pathways without β-arrestin recruitment are an active area of therapeutic development.

Peptide Modulators

Selank is reported to inhibit enkephalin-degrading peptidases, prolonging endogenous enkephalin action and producing anxiolytic effects without direct receptor binding. DSIP is studied for its interactions with opioid-mediated sleep and stress pathways. BPC-157 is investigated for effects on pain and inflammation that may partly involve opioid receptor modulation. Melanotan II, while primarily a melanocortin agonist, reaches circuits with tight POMC co-regulation.